Gilead Layoffsindexp Ornh - Insight Corner

Gilead Sciences (NasdaqGS:GILD) received expanded European Commission approval for Trodelvy in combination with Keytruda as a first-line treatment for metastatic triple-negative breast cancer across ... What Does Gilead Sciences (GILD) Gain From Its Expanded EU Breast Cancer Approval? FiercePharma: Gilead, Teva prevail in high-stakes trial over HIV drug pay-for-delay claims Gilead and Teva have chalked up an important legal victory in a California court, defeating allegations that they created an anticompetitive scheme to delay generic competition to lucrative HIV ... Business Wire: Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc.

General Overview

Business Wire: Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% ... Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis Yahoo Finance: What Does Gilead Sciences (GILD) Gain From Its Expanded EU Breast Cancer Approval? You can also find further discussion and additional details at Docket Search Philadelphia offers a detailed breakdown on this subject. (Nasdaq: GILD) today announced that the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) has been discontinued due to ... Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS